^
Association details:
| Biomarker: | KRAS Q61H |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | Erbitux (cetuximab) (EGFR inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Mutations of KRAS/NRAS/BRAF predict cetuximab resistance in metastatic colorectal cancer patients
Excerpt:
Activating mutations in a few well-characterized loci were detected in the KRAS and NRAS genes (Figure 3A, 3B). For example, two Q61L (exon 3), one Q61H (exon 3), and one A146T (exon 4) KRAS mutations were detected in the non-responders.
DOI:
10.18632/oncotarget.8076
